These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 3729592)

  • 21. Oxidative activation of proguanil and dapsone acetylation in Thai soldiers.
    Edstein MD; Shanks GD; Teja-Isavadharm P; Rieckmann KH; Webster HK
    Br J Clin Pharmacol; 1994 Jan; 37(1):67-70. PubMed ID: 8148220
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Action of proguanil and its metabolite on neuromuscular and synaptic transmission.
    DALLEMAGNE MJ; PHILIPPOT E
    Br J Pharmacol Chemother; 1955 Jun; 10(2):147-52. PubMed ID: 14389651
    [No Abstract]   [Full Text] [Related]  

  • 23. Proguanil, the isolation of a metabolite with high antimalarial activity.
    CROWTHER AF; LEVI AA
    Br J Pharmacol Chemother; 1953 Mar; 8(1):93-7. PubMed ID: 13066702
    [No Abstract]   [Full Text] [Related]  

  • 24. The mode of action of proguanil and related antimalarial drugs.
    RYLEY JF
    Br J Pharmacol Chemother; 1953 Dec; 8(4):424-30. PubMed ID: 13115632
    [No Abstract]   [Full Text] [Related]  

  • 25. The effect of cirrhosis on the disposition and elimination of meperidine in man.
    Klotz U; McHorse TS; Wilkinson GR; Schenker S
    Clin Pharmacol Ther; 1974 Oct; 16(4):667-75. PubMed ID: 4419525
    [No Abstract]   [Full Text] [Related]  

  • 26. Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing.
    Thevis M; Geyer H; Thomas A; Tretzel L; Bailloux I; Buisson C; Lasne F; Schaefer MS; Kienbaum P; Mueller-Stoever I; Schänzer W
    J Pharm Biomed Anal; 2015 Nov; 115():208-13. PubMed ID: 26226108
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism.
    Somogyi AA; Reinhard HA; Bochner F
    Br J Clin Pharmacol; 1996 Mar; 41(3):175-9. PubMed ID: 8866915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between proguanil and metabolites in plasma and saliva.
    Alexander C; Nathwani D; Zimbler N; Taylor RB
    J Antimicrob Chemother; 1995 Dec; 36(6):1113-5. PubMed ID: 8821621
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of S-mephenytoin hydroxylase (CYP2C19) in the metabolism of the antimalarial biguanides.
    Wright JD; Helsby NA; Ward SA
    Br J Clin Pharmacol; 1995 Apr; 39(4):441-4. PubMed ID: 7640152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Atovaquone and proguanil for the treatment of malaria in Brazil.
    de Alencar FE; Cerutti C; Durlacher RR; Boulos M; Alves FP; Milhous W; Pang LW
    J Infect Dis; 1997 Jun; 175(6):1544-7. PubMed ID: 9180204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.
    Birkett DJ; Rees D; Andersson T; Gonzalez FJ; Miners JO; Veronese ME
    Br J Clin Pharmacol; 1994 May; 37(5):413-20. PubMed ID: 8054246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The multiple dose pharmacokinetics of proguanil.
    Helsby NA; Edwards G; Breckenridge AM; Ward SA
    Br J Clin Pharmacol; 1993 Jun; 35(6):653-6. PubMed ID: 8329294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil.
    van Vugt M; Leonardi E; Phaipun L; Slight T; Thway KL; McGready R; Brockman A; Villegas L; Looareesuwan S; White NJ; Nosten F
    Clin Infect Dis; 2002 Dec; 35(12):1498-504. PubMed ID: 12471569
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of effect of proguanil on the pharmacokinetics of dapsone in healthy volunteers.
    Edstein MD; Rieckmann KH
    Chemotherapy; 1993; 39(4):235-41. PubMed ID: 8325124
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations.
    Kaneko A; Bergqvist Y; Taleo G; Kobayakawa T; Ishizaki T; Björkman A
    Pharmacogenetics; 1999 Jun; 9(3):317-26. PubMed ID: 10471063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of atovaquone/proguanil compared with mefloquine for treatment of acute Plasmodium falciparum malaria in Thailand.
    Looareesuwan S; Wilairatana P; Chalermarut K; Rattanapong Y; Canfield CJ; Hutchinson DB
    Am J Trop Med Hyg; 1999 Apr; 60(4):526-32. PubMed ID: 10348224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preventing malaria.
    Fleming AF
    S Afr Med J; 1993 May; 83(5):368-9; author reply 370. PubMed ID: 8211443
    [No Abstract]   [Full Text] [Related]  

  • 38. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu.
    Kaneko A; Kaneko O; Taleo G; Björkman A; Kobayakawa T
    Lancet; 1997 Mar; 349(9056):921-2. PubMed ID: 9093256
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children.
    Lell B; Luckner D; Ndjavé M; Scott T; Kremsner PG
    Lancet; 1998 Mar; 351(9104):709-13. PubMed ID: 9504515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Atovaquone-proguanil for recrudescent Plasmodium falciparum in Vietnam.
    Giao PT; De Vries PJ; Hung LQ; Binh TQ; Nam NV; Kager PA
    Ann Trop Med Parasitol; 2003 Sep; 97(6):575-80. PubMed ID: 14511555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.